[go: up one dir, main page]

EE200100655A - Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-amiintsitraadi polümorfid kui NK-1 retseptori antagonistid - Google Patents

Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-amiintsitraadi polümorfid kui NK-1 retseptori antagonistid

Info

Publication number
EE200100655A
EE200100655A EEP200100655A EEP200100655A EE200100655A EE 200100655 A EE200100655 A EE 200100655A EE P200100655 A EEP200100655 A EE P200100655A EE P200100655 A EEP200100655 A EE P200100655A EE 200100655 A EE200100655 A EE 200100655A
Authority
EE
Estonia
Prior art keywords
crystalline
benzhydryl
azabicyclo
methoxybenzyl
oct
Prior art date
Application number
EEP200100655A
Other languages
English (en)
Estonian (et)
Inventor
Sargent Massett Stephen
Joseph Quallich George
Robert Rose Peter
Theophilus Wint Lewin
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200100655A publication Critical patent/EE200100655A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200100655A 1999-06-01 2000-05-17 Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-amiintsitraadi polümorfid kui NK-1 retseptori antagonistid EE200100655A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13699599P 1999-06-01 1999-06-01
PCT/IB2000/000663 WO2000073303A1 (en) 1999-06-01 2000-05-17 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists

Publications (1)

Publication Number Publication Date
EE200100655A true EE200100655A (et) 2003-02-17

Family

ID=22475353

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100655A EE200100655A (et) 1999-06-01 2000-05-17 Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-amiintsitraadi polümorfid kui NK-1 retseptori antagonistid

Country Status (38)

Country Link
US (1) US6387925B1 (xx)
EP (1) EP1181289A1 (xx)
JP (1) JP2003501353A (xx)
KR (1) KR20020005055A (xx)
CN (1) CN1353712A (xx)
AP (1) AP2001002350A0 (xx)
AR (1) AR029753A1 (xx)
AU (1) AU767331B2 (xx)
BG (1) BG106139A (xx)
BR (1) BR0011125A (xx)
CA (1) CA2372236A1 (xx)
CO (1) CO5170468A1 (xx)
CR (1) CR6513A (xx)
CZ (1) CZ20014270A3 (xx)
DZ (1) DZ3051A1 (xx)
EA (1) EA004206B1 (xx)
EE (1) EE200100655A (xx)
GT (1) GT200000086A (xx)
HK (1) HK1046407A1 (xx)
HN (1) HN2000000076A (xx)
HR (1) HRP20010884A2 (xx)
HU (1) HUP0201798A3 (xx)
IL (1) IL145952A0 (xx)
IS (1) IS6129A (xx)
MX (1) MXPA01012328A (xx)
NO (1) NO20015845L (xx)
NZ (1) NZ514762A (xx)
OA (1) OA11955A (xx)
PA (1) PA8496001A1 (xx)
PE (1) PE20010155A1 (xx)
PL (1) PL352715A1 (xx)
SK (1) SK17342001A3 (xx)
SV (1) SV2002000092A (xx)
TN (1) TNSN00119A1 (xx)
TR (1) TR200103472T2 (xx)
UY (1) UY26177A1 (xx)
WO (1) WO2000073303A1 (xx)
ZA (1) ZA200109839B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031191A1 (en) * 2002-10-04 2004-04-15 Merck Sharp & Dohme Limited Azabicyclic spiroether derivatives as receptor antagonists
CA2529820A1 (en) * 2003-06-18 2004-12-29 Teva Pharmaceutical Industries Ltd Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
US7371906B2 (en) 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN110577522B (zh) * 2018-06-07 2022-12-27 东莞市东阳光动物保健药品有限公司 马罗匹坦柠檬酸盐新晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
JPH0733386B2 (ja) * 1991-05-31 1995-04-12 フアイザー・インコーポレイテツド キヌクリジン誘導体
AU676489B2 (en) * 1992-11-12 1997-03-13 Pfizer Inc. Quinuclidine derivative as substance P antagonist
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions

Also Published As

Publication number Publication date
EA200100982A1 (ru) 2002-06-27
AU767331B2 (en) 2003-11-06
NO20015845D0 (no) 2001-11-30
ZA200109839B (en) 2003-01-29
NO20015845L (no) 2002-01-30
KR20020005055A (ko) 2002-01-16
BG106139A (bg) 2002-05-31
UY26177A1 (es) 2000-12-29
IS6129A (is) 2001-10-26
JP2003501353A (ja) 2003-01-14
HK1046407A1 (zh) 2003-01-10
HN2000000076A (es) 2001-02-02
TNSN00119A1 (fr) 2005-11-10
CA2372236A1 (en) 2000-12-07
WO2000073303A1 (en) 2000-12-07
US6387925B1 (en) 2002-05-14
AR029753A1 (es) 2003-07-16
SV2002000092A (es) 2002-02-05
PA8496001A1 (es) 2002-07-30
MXPA01012328A (es) 2002-07-30
BR0011125A (pt) 2002-02-19
HUP0201798A3 (en) 2002-10-28
TR200103472T2 (tr) 2002-05-21
OA11955A (en) 2006-04-13
EP1181289A1 (en) 2002-02-27
CO5170468A1 (es) 2002-06-27
CZ20014270A3 (cs) 2002-08-14
PE20010155A1 (es) 2001-02-08
SK17342001A3 (sk) 2002-10-08
NZ514762A (en) 2002-12-20
HUP0201798A2 (en) 2002-09-28
AU4424600A (en) 2000-12-18
DZ3051A1 (fr) 2004-03-27
CN1353712A (zh) 2002-06-12
IL145952A0 (en) 2002-07-25
EA004206B1 (ru) 2004-02-26
AP2001002350A0 (en) 2001-12-31
CR6513A (es) 2003-11-25
PL352715A1 (en) 2003-09-08
HRP20010884A2 (en) 2003-04-30
GT200000086A (es) 2001-11-21

Similar Documents

Publication Publication Date Title
IL157815A0 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
AU6751301A (en) 1,3,8-triaza-spiro'4,5]decan-4-one derivatives as neurokinin receptor antagonists
DK1129088T3 (da) Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben
AU7584400A (en) Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions
WO2002012442A3 (en) Heterocyclic compounds as ligands of the gabaa receptor
HUP0301671A3 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
PL356034A1 (en) Cyclic amine compounds as ccr5 antagonists
AU2002341123A1 (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
IL153834A0 (en) N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
AU2002352447A1 (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
PL342692A1 (en) Derivatives of 2-arylethyl-(piperidin-4-ylmethyl)amine as antagonists of muscarinic receptor
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
HUP0202034A3 (en) Heterocyclic substituted aminoazacycles useful as central nervous system agents
HUP0200281A3 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists, process for their preparation and pharmaceutical compositions containing them
EE200100698A (et) Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-ammooniumk loriidi polümorfid kui NK-1 retseptori antagonistid
EE200100655A (et) Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-amiintsitraadi polümorfid kui NK-1 retseptori antagonistid
EE200100214A (et) Ureidopiperidiini derivaadid kui inimese NK3 retseptorite selektiivsed antagonistid
AP2001002072A0 (en) Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride
PL340756A1 (en) Novel heterocyclic ring substituted derivatives of alpha-hydroxycarboxylic acid, method of obtaining said derivatives and their application as antagonists of endoethelin receptor
AU2002354104A1 (en) Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
IL123740A0 (en) NK-1 receptor antagonists for the treatment of delayed emesis
TW422077U (en) Improved structure of chuck for mop
HK1065028A (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
HK1067366A (en) Lactam derivatives as antagonists for human 11cby receptors